Related Experiment Videos
Antithrombotic therapy in native heart valve disease
1Klinik am See, Department of Cardiology, Rehabilitation Center of Cardiovascular Diseases, Seebad 84, D-15562 Rüdersdorf/Berlin, Germany. heinz.voeller@klinikamsee.com
The Journal of Heart Valve Disease
|June 30, 2004
Summary
Anticoagulation is recommended for patients with heart valve disease and atrial fibrillation (AF) or thromboembolic events. Differentiated approaches are needed for patients in sinus rhythm, considering specific risk factors for stroke.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Native heart valve disease management requires distinguishing between patients with atrial fibrillation (AF) and those in sinus rhythm for anticoagulation decisions.
- Thromboembolic events and AF are primary indications for anticoagulation in non-valve replacement patients.
- Sinus rhythm patients require a nuanced approach based on specific cardiac conditions and risk factors.
Purpose of the Study:
- To outline differentiated anticoagulation strategies for patients with native heart valve disease.
- To clarify indications for anticoagulation in patients with sinus rhythm and specific cardiac conditions.
- To differentiate management of embolic sources in various valvular and congenital heart conditions.
Main Methods:
- Review of clinical guidelines and evidence for anticoagulation in native heart valve disease.
- Analysis of risk factors and embolic sources in patients with sinus rhythm.
- Comparison of anticoagulation indications based on specific valve pathologies (mitral stenosis, aortic stenosis) and congenital defects.
Main Results:
- Anticoagulation is indicated for thromboembolic events/AF unless valve replacement is performed.
- In sinus rhythm, anticoagulation (target INR 2.5) is indicated with left atrial enlargement, spontaneous echo contrast, absent atrial contraction, or reduced left ventricular function, particularly in mitral valve stenosis.
- Anticoagulation is not recommended for calcific microemboli in aortic stenosis; warfarin is indicated for aortic arch atherothrombotic plaques >5mm. Congenital lesions like MVP do not warrant anticoagulation alone, with aspirin recommended for secondary stroke prevention in MVP.
Conclusions:
- Anticoagulation decisions in native heart valve disease must be tailored to rhythm status and specific cardiac findings.
- Patients with sinus rhythm and specific risk factors (e.g., enlarged left atrium, impaired ventricular function) benefit from anticoagulation.
- Management of embolic risk varies significantly based on the underlying cause, with distinct strategies for valvular and congenital heart disease.